Clinical trials: Common Warts (Verruca Vulgaris)
Verruca Viral
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
Common warts are papulonodular epidermal lesions caused by human papillomavirus (HPV) usually by the strains 1, 2, 4, 27 or 57. Cutaneous warts occur in 7% to 10% of the general population, with a maximum incidence between 12 and…
- Trial name
- MMR (NCT04428359)
- Testing
- Measles-Mumps-Rubella Vaccine, Vit D
- Where
- Nepal
- Volunteers
- 66 people
- Sponsor
- B.P. Koirala Institute of Health Sciences
Verruca Vulgaris
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin
The purpose of the study was to see if liquid nitrogen, a commonly used treatment for warts, is more effective if it is used alone, or if it is more effective if combined with cantharidin, a topical treatment also commonly used…
- Trial name
- NCT01084824
- Testing
- Liquid nitrogen and cantharidin
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- North Idaho Dermatology
Warts
The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)
Verruca vulgaris, otherwise known as the common wart, is caused by the human papillomavirus (HPV). Common warts are generally located on the hands and feet, but can also occur elsewhere (e.g., any areas of frequent contact).
- Trial name
- NCT00546611
- Testing
- PEP005
- Where
- Australia
- Sponsor
- Peplin
Warts, Verruca (Warts)
Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts
This study will evaluate whether Gardasil-9, a vaccine normally used to prevent human papillomavirus (HPV) infection, may be effective for treating recurring warts that have not responded to standard treatments.
- Conditions
- Warts, Verruca (Warts), Verruca Vulgaris
- Trial name
- NCT07806617
- Testing
- 9-valent human papillomavirus vaccine, Sterile Saline
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Rush University Medical Center
Verruca Viral
Gardasil Versus Cervarix in the Treatment of Warts
Warts are common, benign, epidermal proliferations caused by HPV infecting skin and mucous membranes. Treatment of warts poses a true challenge despite existing variable therapeutic modalities, whether destructive or…
- Trial name
- NCT05383625
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Bivalent Human Papilloma Virus Vaccine, Saline
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Zagazig University
Verruca Plantaris
A Randomized Controlled Trial to Evaluate the Effectiveness of Bleomycin and Cryotherapy in Treating Plantar Warts.
To evaluate the efficacy of bleomycin and cryopreservation in the treatment of plantar verruca by dermoscopy and explore the influencing factors.
- Trial name
- NCT06718192
- Testing
- Bleomycin injection, Cryotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Plantar Wart
Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts
Plantar warts can be bothersome and painful requiring treatment. The investigators will compare the efficacy of pyruvic acid and salicylic acid in treating multiple plantar warts.
- Trial name
- NCT02151630
- Testing
- Pyruvic acid, Salicylic Acid
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Isfahan University of Medical Sciences
Verruca Vulgaris, Molluscum Contagiosum Skin Infection
Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum.
- Trial name
- NCT05070754
- Testing
- Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP), Cryotherapy, Canthardin Collodion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical University of South Carolina
Warts
Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
This is a placebo-controlled, double-blind (subject, Investigator, and site staff with the exception of unblinded dedicated staff to handle study medication), phase 2a study with 3 dose cohorts, randomized (concealed) to CANDIN…
- Trial name
- NCT02393417
- Testing
- CANDIN
- Where
- 15 sites in United States
- Volunteers
- 243 people
- Sponsor
- Nielsen BioSciences, Inc.
Verruca, Warts
Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study
The purpose of this study is to investigate topical treatment with Veregen™ 15% ointment as a single therapeutic agent and compare it to combination therapy with Veregen ™ 15% ointment and a single destructive treatment by…
- Trial name
- NCT02622568
- Testing
- Veregen only, Cryotherapy and Veregen
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Verruca Vulgaris
ALC-919 For The Treatment Of Common Warts
This is a single-center, randomized, double blind, vehicle-controlled phase 2 study of subjects 8 years of age and older with Common Warts (Verruca vulgaris) who desire treatment.
- Trial name
- NCT02483455
- Testing
- 2014-ALC-919-US, Vehicle-Control Topical Solution
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Veloce BioPharma LLC
Verruca Vulgaris, Molluscum Contagiosum
Cold Atmospheric Plasma Device Extension Study
Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one…
- Trial name
- NCT05937672
- Testing
- Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Verruca Vulgaris, Involucrin
Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study
Vitamin D3 plays important role in keratinocyte differentiation and had been used recently in verruca vulgaris. Aim of the work: To assess the expression of involucrin in verrucae vulgaris before and after injection of vitamin…
- Trial name
- NCT04793529
- Testing
- Cholecalciferol
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Benha University
Common Warts, HPV (Human Papillomavirus)
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata…
- Conditions
- Common Warts, HPV (Human Papillomavirus), Periungual Warts, Plantar Warts
- Trial name
- NCT02640820
- Testing
- Sensitizing DPCP Ointment, Treatment DPCP Ointment
- Where
- 4 sites in United States
- Volunteers
- 83 people
- Sponsor
- RXi Pharmaceuticals, Corp.
Common Warts
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts
Nonclinical studies have shown sandalwood oil to have anti-inflammatory, anti-fungal, antiviral, and anti-bacterial activities. Previous clinical studies have shown East Indian Sandalwood oil to be promising as a treatment for…
- Trial name
- NCT01286441
- Testing
- 10% EISO, 20% EISO, 30% EISO
- Where
- 20 sites in United States
- Volunteers
- 183 people
- Sponsor
- ViroXis Corporation
Common Warts (Verruca Vulgaris)
New Treatment of Common Wart
this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts.
- Trial name
- NCT07543926
- Testing
- PRF group, Vitamin D
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Sohag University
Warts
Microwave Treatment of Common and Plantar Warts
This is a multi-center, open, randomized, parallel-group, controlled, blind-assessed trial of approximately 124 subjects that require treatment for up to 5 common or plantar warts.
- Trial name
- NCT05371834
- Testing
- Microwave Treatment (Swift System), Cryotherapy
- Where
- 6 sites in United States
- Volunteers
- 119 people
- Sponsor
- Blackwell Device Consulting
Common Wart, Warts Hand
Cantharidin and Occlusion in Verruca Epithelium
This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common…
- Conditions
- Common Wart, Warts Hand, Warts, Papillomavirus Infections
- Trial name
- COVE-1 (NCT03487549)
- Testing
- VP-102 Cantharidin topical film forming solution, VP-102 Cantharidin, topical film forming solution
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Viral Wart, Plantar Wart
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
The goal of this clinical trial is to learn if injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts works to clear them in people aged 12 and older with common, plantar, flat, or periungual (around the…
- Conditions
- Viral Wart, Plantar Wart, Common Warts (Verruca Vulgaris), Common Wart
- Trial name
- NCT07448844
- Testing
- Intralesional Acyclovir, Intralesional Vitamin D3
- Where
- 2 sites in Pakistan
- Volunteers
- 40 people
- Sponsor
- Riphah International University
Common Wart
Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.
- Trial name
- NCT01796795
- Testing
- Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM
- Volunteers
- 102 people
- Sponsor
- G&E Herbal Biotechnology Co., LTD